EMD Serono [clinicaltrials_resource:b2b1c91cbcef15ce75de6ad897745af7]
Jonathan Willmer, MD [clinicaltrials_resource:06e5f25787591ff58ed44c9b01e38d42]Medical Responsible [clinicaltrials_resource:0b829ec395844d37a5366bfc163ff5bc]Steven J. Greenberg, M.D. [clinicaltrials_resource:25ac7c5bb78ea2a389b1fee11d86b4e3]Donald R Tredway, M.D., PhD [clinicaltrials_resource:300a5b092f7137f19918d34c41338fc4]Dan Mikol, MD [clinicaltrials_resource:37e68bc11984a5518fc35647d916665f]Phil Breitfeld, MD [clinicaltrials_resource:41574cfa55c60c962a8ae378ee3ebc17]Sanja Dragnic, MD [clinicaltrials_resource:41627a9e684fb89890b16a61246582b5]Dan Mikol, MD, PhD [clinicaltrials_resource:4c06d5758cd86292cc3503a014058da8]Mary Mahony, PhD, HCLD (AAB) [clinicaltrials_resource:4e1a98962c90d1d4f9fe6f96a410ca3d]Medical Responsible [clinicaltrials_resource:54f7e34d30cd57e059bdbf55b1713faa]Medical Responsible [clinicaltrials_resource:554cc6024d77b6df88e704549ae0f301]Fernando Dangond, MD [clinicaltrials_resource:555abee77f5e3c58d57edcb54dbc3653]Randy Bennett [clinicaltrials_resource:55f95044249df32f5530837c720baf15]Daniel Mikol, MD, PhD [clinicaltrials_resource:5dbb175736216b11337685130c47935f]Norma Muurahainen, M.D. PhD [clinicaltrials_resource:74fea9fed58e08996260c51cedd02f07]Eduardo Kelly, MD, MBA [clinicaltrials_resource:8a888ecc00ccc4761ef29fc90fb02a17]Ellen Brady, M.D. MPH [clinicaltrials_resource:bd7d5702c19bfd627755c12334daf03d]Claudia Pena Rossi, M.D. [clinicaltrials_resource:cdd71f9641109ba65d7467842bd0abd6]Bruno Musch, MD [clinicaltrials_resource:d1aebc279fa48cb8a8d023132791c138]Oscar Kashala, MD, PhD, DSc [clinicaltrials_resource:eb69a7333077ab789cd4a0a1d2bad96c]Zourab Bebia, MD [clinicaltrials_resource:f98416fa5bb10e0abe61a3ccb8d03805]
affiliation [clinicaltrials_vocabulary:affiliation]
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment [clinicaltrials:NCT00016237]Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis [clinicaltrials:NCT00078338]clinicaltrials:NCT00110396A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects [clinicaltrials:NCT00249860]Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects [clinicaltrials:NCT00292253]A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS) [clinicaltrials:NCT00292266]Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis [clinicaltrials:NCT00303381]clinicaltrials:NCT00338741clinicaltrials:NCT00409188clinicaltrials:NCT00428584A Phase II Dose-finding Study of Atacicept in Rheumatoid Arthritis (RA) [clinicaltrials:NCT00430495]The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis [clinicaltrials:NCT00573157]clinicaltrials:NCT00689221clinicaltrials:NCT00813943clinicaltrials:NCT01226745Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors [clinicaltrials:NCT01390818]clinicaltrials:NCT01496131clinicaltrials:NCT01746979clinicaltrials:NCT01919164clinicaltrials:NCT01936363clinicaltrials:NCT02047500
collaborator [clinicaltrials_vocabulary:collaborator]
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment [clinicaltrials:NCT00016237]A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer [clinicaltrials:NCT00073541]Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis [clinicaltrials:NCT00078338]Treatment of Abnormal Adipose Tissue Accumulation in HIV Patients [clinicaltrials:NCT00082628]Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis [clinicaltrials:NCT00090129]Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) [clinicaltrials:NCT00093964]Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects [clinicaltrials:NCT00101959]Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia [clinicaltrials:NCT00105508]Sarizotan HCl in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia [clinicaltrials:NCT00105521]clinicaltrials:NCT00109733clinicaltrials:NCT00110396Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer [clinicaltrials:NCT00111839]EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide [clinicaltrials:NCT00132522]clinicaltrials:NCT00213135Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction [clinicaltrials:NCT00213148]A Phase 3b Study to Evaluate Subject Satisfaction With Follitropin Alfa Injection in Oligoanovulatory Infertile Women Undergoing Ovulation Induction [clinicaltrials:NCT00230815]A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects [clinicaltrials:NCT00249860]clinicaltrials:NCT00262314Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects [clinicaltrials:NCT00292253]A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS) [clinicaltrials:NCT00292266]Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS) [clinicaltrials:NCT00294164]An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome [clinicaltrials:NCT00294918]A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation [clinicaltrials:NCT00298025]Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis [clinicaltrials:NCT00303381]Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease [clinicaltrials:NCT00304252]Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia [clinicaltrials:NCT00314288]clinicaltrials:NCT00328926clinicaltrials:NCT00338741AS703569 Phase I in Patients With Solid Tumours [clinicaltrials:NCT00391521]ATS-1 Needle Free Injection Device Study-a Device for Administering r-hGH (Saizen) to Treat Growth Hormone Deficiency [clinicaltrials:NCT00407472]Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. [clinicaltrials:NCT00408967]clinicaltrials:NCT00409188clinicaltrials:NCT00428584A Phase II Dose-finding Study of Atacicept in Rheumatoid Arthritis (RA) [clinicaltrials:NCT00430495]clinicaltrials:NCT00436826clinicaltrials:NCT00472797Growth Hormone in the Treatment of HIV-Associated Wasting [clinicaltrials:NCT00489528]The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis [clinicaltrials:NCT00573157]Study of Atacicept in Anti-TNFα-naïve Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate [clinicaltrials:NCT00595413]Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus [clinicaltrials:NCT00624338]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
organization [clinicaltrials_vocabulary:organization]
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment [clinicaltrials:NCT00016237]A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer [clinicaltrials:NCT00073541]Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis [clinicaltrials:NCT00078338]Treatment of Abnormal Adipose Tissue Accumulation in HIV Patients [clinicaltrials:NCT00082628]Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis [clinicaltrials:NCT00090129]Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) [clinicaltrials:NCT00093964]Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects [clinicaltrials:NCT00101959]Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia [clinicaltrials:NCT00105508]Sarizotan HCl in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia [clinicaltrials:NCT00105521]clinicaltrials:NCT00109733clinicaltrials:NCT00110396Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer [clinicaltrials:NCT00111839]EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide [clinicaltrials:NCT00132522]clinicaltrials:NCT00213135Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction [clinicaltrials:NCT00213148]A Phase 3b Study to Evaluate Subject Satisfaction With Follitropin Alfa Injection in Oligoanovulatory Infertile Women Undergoing Ovulation Induction [clinicaltrials:NCT00230815]A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects [clinicaltrials:NCT00249860]clinicaltrials:NCT00262314Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects [clinicaltrials:NCT00292253]A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS) [clinicaltrials:NCT00292266]Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS) [clinicaltrials:NCT00294164]An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome [clinicaltrials:NCT00294918]A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation [clinicaltrials:NCT00298025]Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis [clinicaltrials:NCT00303381]Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease [clinicaltrials:NCT00304252]Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia [clinicaltrials:NCT00314288]clinicaltrials:NCT00328926clinicaltrials:NCT00338741AS703569 Phase I in Patients With Solid Tumours [clinicaltrials:NCT00391521]ATS-1 Needle Free Injection Device Study-a Device for Administering r-hGH (Saizen) to Treat Growth Hormone Deficiency [clinicaltrials:NCT00407472]Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. [clinicaltrials:NCT00408967]clinicaltrials:NCT00409188clinicaltrials:NCT00428584A Phase II Dose-finding Study of Atacicept in Rheumatoid Arthritis (RA) [clinicaltrials:NCT00430495]clinicaltrials:NCT00436826clinicaltrials:NCT00472797Growth Hormone in the Treatment of HIV-Associated Wasting [clinicaltrials:NCT00489528]The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis [clinicaltrials:NCT00573157]Study of Atacicept in Anti-TNFα-naïve Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate [clinicaltrials:NCT00595413]Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus [clinicaltrials:NCT00624338]
source [clinicaltrials_vocabulary:source]
EMD Serono [clinicaltrials_resource:b2b1c91cbcef15ce75de6ad897745af7]
Bio2RDF identifier
b2b1c91cbcef15ce75de6ad897745af7
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:b2b1c91cbcef15ce75de6ad897745af7
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:b2b1c91cbcef15ce75de6ad897745af7
title
EMD Serono
@en
type
label
EMD Serono [clinicaltrials_resource:b2b1c91cbcef15ce75de6ad897745af7]
@en